Condition: Alzheimer Disease · Sponsor: Alpha Cognition, Inc
The primary purpose of this study is to evaluate the safety and tolerability of Zunveyl® over 12 weeks of routine clinical use in adults with mild to moderate Alzheimer's disease.
This description comes directly from the study's public registry record.
Kurt P Grady, MBA · (618) 407-6732 · kgrady@alphacognition.com
Always discuss trial participation with your own doctor first.
| CCM Clinical Research Group, LLC | Miami, Florida, United States | Recruiting |
| Progressive Medical Research | Port Orange, Florida, United States | Recruiting |
| Essential Concepts Research Solutions (ECRS) | Palos Hills, Illinois, United States | Recruiting |
| Tekton Research Saint Louis Psychiatry | St Louis, Missouri, United States | Recruiting |
| Alzheimer's Disease Research Center | Albany, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07633470